Compare PBF & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBF | ORKA |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.4B |
| IPO Year | 2011 | 1997 |
| Metric | PBF | ORKA |
|---|---|---|
| Price | $66.11 | $108.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $84.14 | ★ $156.17 |
| AVG Volume (30 Days) | ★ 2.7M | 858.7K |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 69.78 | N/A |
| EPS | ★ 21.82 | N/A |
| Revenue | ★ $24,508,200,000.00 | N/A |
| Revenue This Year | $46.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.62 | $25.23 |
| 52 Week High | $92.46 | $115.52 |
| Indicator | PBF | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 71.98 |
| Support Level | $58.42 | $83.25 |
| Resistance Level | $68.33 | $115.52 |
| Average True Range (ATR) | 4.66 | 5.94 |
| MACD | -1.49 | 2.20 |
| Stochastic Oscillator | 2.68 | 89.91 |
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines, and storage facilities. The Logistics segment consists solely of PBFX's operations.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.